Efecto del tratamiento antihipertensivo en la calidad de vida de los pacientes con rinosinusitis crónica con pólipos nasales

IF 0.9 Q3 OTORHINOLARYNGOLOGY

Acta otorrinolaringologica espanola Pub Date : 2024-05-01 DOI:10.1016/j.otorri.2023.08.001

Juan Maza-Solano , Carmen Palma-Martínez , Daniel Martín-Jiménez , Serafín Sánchez-Gómez , Ramón Moreno-Luna , Christian Calvo-Henriquez , Hugo Galera-Ruiz

{"title":"Efecto del tratamiento antihipertensivo en la calidad de vida de los pacientes con rinosinusitis crónica con pólipos nasales","authors":"Juan Maza-Solano , Carmen Palma-Martínez , Daniel Martín-Jiménez , Serafín Sánchez-Gómez , Ramón Moreno-Luna , Christian Calvo-Henriquez , Hugo Galera-Ruiz","doi":"10.1016/j.otorri.2023.08.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Aim</h3><p>Nasal polyposis (CRSwNP) shares type2 inflammation biomarkers with asthma, allergy or arterial hypertension (AH), including periostin, a predictive marker of severity and post-surgical recurrence of polyposis. Antihypertensives have been shown to decrease periostin expression. We set out to evaluate the effect of antihypertensives on the quality of life of patients with CRSwNP.</p></div><div><h3>Materials and methods</h3><p>Retrospective study of 43 patients with CRSwNP and AH with at least 1year of follow-up and antihypertensive treatment prescribed after the diagnosis of CRSwNP. Phenotypes were analyzed (F1: isolated CRSwNP; F2: CRSwNP with asthma and/or NERD) and aspects related to quality of life (SNOT-22), clinical severity (VAS), polypoid size (NPS), exacerbations and surgical needs after the initiation of antihypertensive treatment.</p></div><div><h3>Results</h3><p>The predominant phenotype was F1 (62.8%). The number of exacerbations was 19.2% for F1, compared to 31.3% for F2. 34.8% underwent surgery after the start of antihypertensive treatment (F1=27.9% and F2=6.97%). A significant reduction in polypoid size, SNOT22 (16.4±19.6 points), and VAS scales (<em>P</em>  <!-->.05) was obtained.</p></div><div><h3>Conclusions</h3><p>Antihypertensives administered in patients with CRSwNP and comorbid AH improve quality of life, reduce polypoid size, and reduce the risk of postoperative recurrence.</p></div>","PeriodicalId":7019,"journal":{"name":"Acta otorrinolaringologica espanola","volume":"75 3","pages":"Pages 155-161"},"PeriodicalIF":0.9000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta otorrinolaringologica espanola","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0001651923001164","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim

Nasal polyposis (CRSwNP) shares type 2 inflammation biomarkers with asthma, allergy or arterial hypertension (AH), including periostin, a predictive marker of severity and post-surgical recurrence of polyposis. Antihypertensives have been shown to decrease periostin expression. We set out to evaluate the effect of antihypertensives on the quality of life of patients with CRSwNP.

Materials and methods

Retrospective study of 43 patients with CRSwNP and AH with at least 1 year of follow-up and antihypertensive treatment prescribed after the diagnosis of CRSwNP. Phenotypes were analyzed (F1: isolated CRSwNP; F2: CRSwNP with asthma and/or NERD) and aspects related to quality of life (SNOT-22), clinical severity (VAS), polypoid size (NPS), exacerbations and surgical needs after the initiation of antihypertensive treatment.

Results

The predominant phenotype was F1 (62.8%). The number of exacerbations was 19.2% for F1, compared to 31.3% for F2. 34.8% underwent surgery after the start of antihypertensive treatment (F1 = 27.9% and F2 = 6.97%). A significant reduction in polypoid size, SNOT22 (16.4 ± 19.6 points), and VAS scales (P < .05) was obtained.

Conclusions

Antihypertensives administered in patients with CRSwNP and comorbid AH improve quality of life, reduce polypoid size, and reduce the risk of postoperative recurrence.

查看原文本刊更多论文

降压治疗对患有鼻息肉的慢性鼻炎患者生活质量的影响

目的鼻息肉病（CRSwNP）与哮喘、过敏或动脉高血压（AH）具有相同的 2 型炎症生物标志物，其中包括对息肉病的严重程度和手术后复发具有预测作用的标志物--起泡素。有研究表明，抗高血压药物可降低骨膜增生蛋白的表达。材料与方法回顾性研究 43 例 CRSwNP 和 AH 患者，随访至少 1 年，确诊 CRSwNP 后给予降压治疗。研究分析了表型（F1：孤立的 CRSwNP；F2：伴有哮喘和/或 NERD 的 CRSwNP）以及与生活质量（SNOT-22）、临床严重程度（VAS）、息肉大小（NPS）、病情加重和开始降压治疗后的手术需求相关的方面。F1 型患者的病情恶化次数为 19.2%，而 F2 型患者的病情恶化次数为 31.3%。34.8%的患者在开始降压治疗后接受了手术（F1=27.9%，F2=6.97%）。结论对 CRSwNP 和合并 AH 的患者使用降压药可改善生活质量，缩小息肉，降低术后复发风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta otorrinolaringologica espanola OTORHINOLARYNGOLOGY-

CiteScore

1.40

自引率

20.00%

发文量

审稿时长

44 days

期刊介绍： Es la revista más importante en español dedicada a la especialidad. Ofrece progresos científicos y técnicos tanto a nivel de originales como de casos clínicos. Además, es la Publicación Oficial de la Sociedad Española de Otorrinolaringología y Patología Cérvico-Facial y está presente en los más prestigiosos índices de referencia.